IP Library Granted Patent US 12,220,407
Granted Patent B2
US 12,220,407 · App. 18/076,113 · Granted Feb 11, 2025

Life extension for humans and other mammals

Inventor: Richard Postrel (Miami Beach, FL)
A61K31/436A61K31/05A61K31/07A61K31/122A61K31/197A61K31/375A61K31/4188A61K31/4415A61K31/455A61K31/51A61K31/519A61K31/525A61K31/566A61K31/592A61K31/593A61K31/714A61K33/00A61K33/04A61K33/06A61K33/26A61K33/30A61K33/32A61K33/42A61K36/185A61K47/44A61P39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,407
App. No.
18/076,113
Granted
Feb 11, 2025
Kind
B2
Abstract

The present invention discloses a system and method for increasing the lifespan and quality of life of human beings and other mammals. This discloses methods for preparing and delivering various health and longevity compositions. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation, misting, nasal spray, suppository, etc. An existing compound known to have capacity for life extending potential, rapamycin, is combined with a non-toxic therapeutic anabolic hormone, e.g., DHEA, and cannabidiol (CBD) to enable absorption and effect. These three compounds work together to dramatically improve both the quality of life in aging humans and other mammals as well as extending the life of humans potentially up to 120 healthy years. One preferred embodiment provides a method for continuous low dose supplementation, e.g., incorporated in or with a daily meal. This invention not only resolves the issue of anti-aging of higher life forms, without toxicity, but provides for an improved method for absorption.

Claims (22)

1. A composition comprising an androgenic prohormone, rapamycin, and a cannabinoid compound that binds and stimulates a mammalian endocannabinoid receptor.

2. The composition of claim 1 said prohormone is selected from the group consisting of: DHEA, 7-keto DHEA and DHEA-S.

3. The composition of claim 1 wherein said endogenous endocannabinoid receptor is selected from the group consisting of: CB1, CB2, TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, TRPM8, GPR18, GPR119, GPR55, GPR118 and non-human analogues thereto.

4. The composition of claim 1 wherein said cannabinoid compound comprises cannabidiol (CBD).

5. The composition of claim 3 wherein said cannabinoid compound also binds and stimulates at least one 5-HT receptor.

6. The composition of claim 1 further comprising an oil selected from the group consisting of: vegetable, rapeseed/canola, soy, corn, peppermint, lavender, sandalwood, bergamot, rose, chamomile, ylang-ylang, tea tree, myrcene/hops, jasmine, and lemon.

7. The composition of claim 1 further comprising nutmeg or nutmeg extract.

8. The composition of claim 1 present in an edible selected from the group consisting of: a toothpaste, a feed, a spritz, a small treat, a food formulation, a food supplement, a gummi, a prescription food product, a capsule, a pill, a reward, a spray, an ampule, a chewing gum, and a chew toy.

9. A gummi food comprising the composition of claim 1 .

10. A chewing gum comprising the composition of claim 1 .

11. The composition of claim 1 present in a format selected from the group consisting of: a liquid for spritzing into an oral or nasal opening, a liquid for misting, a lozenge, a buccal strip, and a suppository.

12. The composition of claim 11 present in a device comprising a mask or a tube that can deliver said liquid for misting into a nasal passage.

13. The composition of claim 1 further comprising at least one vitamin selected from the group consisting of: vitamin A carotenoids, B1 thiamin, B2 riboflavin, B3 niacin, B5 panthenic acid, B6, pyridoxal, B7 biotin, B9 folic acid/folate, B12 cobalamin, C ascorbate/ascorbic acid, D2 ergocalciferol, D3 cholcalciferol, K1 phylloquinone, K2 menaquinone, retinol, and retinyl ester.

14. The composition of claim 13 further comprising at least one mineral selected from the group consisting of: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

15. The composition of claim 1 further comprising at least one mineral selected from the group consisting of: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

16. A method for providing a safe therapeutic composition to a mammal, said method comprising delivering to said mammal the composition of claim 1 .

17. The method of claim 16 wherein said mammal is a human.

18. The method of claim 16 wherein said mammal is a canine.

19. The method of claim 16 wherein said mammal is an equine.

20. The method of claim 16 wherein said mammal is listed as a member of a threatened or endangered species on a list maintained by the World Wildlife Federation (WWF), the International Union for Conservation of Nature (IUCN), or a local or national government.

21. A method of extending the productive lifespan of a human being, said method comprising providing the composition of claim 1 to said human being.

22. The method of claim 21 wherein said composition is configured for for repeated intake through oral, nasal, rectal, or vaginal delivery.

Continuity (6)
Continuation In Part 17676486 · Feb 21, 2022
Continuation In Part 17227320 · Apr 11, 2021
Continuation In Part 15952230 · Apr 12, 2018
Provisional Application 63151073 · Feb 19, 2021
Provisional Application 62537027 · Jul 26, 2017
Related Publication 20230114740A1 · Apr 13, 2023
References Cited (4)
US 8221809B2 · Subramanian · 2012 [cited by examiner]
US 9480689B1 · McGlone · 2016 [cited by examiner]
US 20180071314A1 · Dunlop · 2018 [cited by examiner]
WO WO2020239784A1 · 2020 [cited by examiner]